Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

@article{Komrokji2015ResultsOA,
  title={Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.},
  author={R. Komrokji and J. Seymour and A. Roberts and M. Wadleigh and L. To and R. Scherber and E. Turba and A. Dorr and Joy Zhu and Lixia Wang and T. Granston and M. Campbell and R. Mesa},
  journal={Blood},
  year={2015},
  volume={125 17},
  pages={
          2649-55
        }
}
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2 study further characterized the safety and efficacy of pacritinib in the treatment of patients with MF. Eligible patients had clinical splenomegaly poorly controlled with standard therapies or were… Expand
92 Citations
Clinical potential of pacritinib in the treatment of myelofibrosis
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Pacritinib: a new agent for the management of myelofibrosis?
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis
Investigational Janus kinase inhibitors in development for myelofibrosis
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
  • A. Younes, J. Romaguera, +12 authors Joy Zhu
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Advances in the management of myelofibrosis.
...
1
2
...